Background: Due to promising results in earlier clinical studies, a confirmatory phase II clinical trial of interferon alpha-2a (IF) and 13-cis-retinoic acid (RA) was conducted in patients with metastatic renal cell carcinoma (mRCC). Patients and Methods:29 previously untreated patients with mRCC were treated. IF was given subcutaneously daily at 3 MU and escalated to 6 and 9 MU if tolerated. The RA dose was 1 mg/kg/day. The treatment was given over a period of 12 weeks, a staging procedure was performed every 6 weeks within the first half year and, thereafter, in 3-month intervals until progressive disease was documented. Results:27 patients were eligible, 24 patients were evaluable for tumor response. 2/24 patients achieved a major response (2 partial responses), 9/24 had a treatment failure (9 progressive diseases), and 13/24 showed a status-idem situation (13 no-change cases). Myelotoxicity, nausea, epidermal toxicity, loss of appetite and weight loss were considerable and occurred inmost of the patients. Conclusions: IF and RA showed less anti-tumor activity than had been anticipated in advanced RCC. The proportion and the nature of response as well as the toxicity pattern suggest the deletion of this combination from the therapeutical repertoire of medical oncologists.

This content is only available via PDF.
© 1999 S. Karger GmbH, Freiburg
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.